PEPTIDE GUARDIANResearch literacy for peptides

Guides

Growth hormone axis: what the research shows

Compounds that act on growth hormone or the signals that control it. This guide covers 4 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

CJC-1295

Early human trials

CJC-1295 is a synthetic analogue of the body's growth-hormone-releasing hormone; the long-acting original was tested only in small early trials in healthy volunteers before its company's trial was halted after a participant died, and the version sold as "no DAC" has never been tested in people at all.

Everything known about CJC-1295 in people comes from three small studies in healthy volunteers, all of the albumin-binding (DAC) form, published between 2006 and 2009 and involving about 63 adults in total, most of whom received a single injection. They showed that the drug raises growth hormone and IGF-1 in blood for days to weeks and that the natural pulsing rhythm of growth hormone is preserved. They measured hormone levels, not health. No trial has shown that CJC-1295 builds muscle, reduces fat, heals injury, improves sleep or does anything else claimed for it. The one trial in patients, a phase 2 study in people with HIV-associated fat redistribution, was terminated and never published. For the molecule sold as "CJC-1295 without DAC" or "Modified GRF 1-29", FDA searched in 2024 and found no human study at all, and no study establishing that it is even pharmacologically active. No trial of CJC-1295 combined with ipamorelin was found on ClinicalTrials.gov; a search of that registry in November 2026 returned three ipamorelin studies, all of ipamorelin alone and none involving a GHRH analogue.

Key studies

  • Human trial, 2009. Using gel separation and mass spectrometry on blood serum, the authors found that two proteins (apolipoprotein A1 and transthyretin) decreased while fragments of albumin, a haemoglobin chain and an immunoglobulin fragment increased. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2006. A single injection raised average growth hormone in blood by two to ten times for six days or more, and IGF-1 by one and a half to three times for 9 to 11 days. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2006. The natural rhythm of growth hormone release was preserved: the number and size of the pulses did not change. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. Advisory committee voted against allowing it for pharmacy compounding.
In sport
Prohibited at all times; named in S2.2.4 (growth hormone releasing factors), 2026 and 2027.

All 12 studies on the CJC-1295 page

IGF-1 LR3

Animal and cell studies only

IGF-1 LR3 is a laboratory-made version of the human growth factor IGF-1, altered so that it slips past the proteins that normally hold IGF-1 inactive; it was built as a research and cell-culture reagent, has never been tested in a published human trial, and is prohibited in sport.

There is none. No published human trial of IGF-1 LR3 was found in PubMed, and ClinicalTrials.gov returned no registered study of it under any of its names. A 2021 anti-doping paper states that these IGF-I analogues have never been approved for human use. The only human exposure described anywhere in the literature opened for this page is unmeasured and uncontrolled: anti-doping laboratories reporting the substance in seized black-market products, in one case unpurified and in another carrying a laboratory purification tag. The whole evidence base is cells, rats, pigs, marmosets, cattle and mice, mostly from one Adelaide group in the 1990s, mostly over a week or two, and mostly measuring growth and nitrogen balance rather than anything a person would notice. A different molecule, plain recombinant human IGF-1 (mecasermin, Increlex), has been an approved medicine since 2005 for one rare childhood growth disorder, and its label is the best available guide to what raising IGF-1 signalling does in people; it is not evidence about this analogue.

Key studies

  • Review, 2010. Women in the highest fifth of natural IGF-1 levels had a 28% higher odds of breast cancer than those in the lowest fifth (odds ratio 1.28, 95% confidence interval 1.14 to 1.44). Source: pubmed.ncbi.nlm.nih.gov
  • Review, 1993. IGF-I binds IGFBP-3, IGFBP-4, the total binding proteins in rat plasma and the L6 myoblast binding protein with roughly a thousandfold greater affinity than the LR3 analogue. Source: pubmed.ncbi.nlm.nih.gov
  • Animal study, 2025. This is the longest treatment study found in any animal, and it is a negative one on the outcome that mattered. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. Not on FDA's compounding lists. Sold only as a research reagent.
In sport
Prohibited at all times; IGF-1 and its analogues are named in S2.3 (growth factors).

All 13 studies on the IGF-1 LR3 page

Ipamorelin

Early human trials

Ipamorelin is a lab-made chain of five amino acids that makes the pituitary gland release growth hormone; a drug company took it into two mid-stage human trials for bowel recovery after surgery, the published one missed its goal, development stopped, and it has never been tested in people for muscle, fat, sleep or ageing.

Almost nothing is established in people, and what was tested, failed. There are exactly two human studies of ipamorelin itself. The first, in 1999, gave healthy men a short infusion into a vein and measured how the peptide and growth hormone rose and fell; it tested no benefit. The second, published in 2014, was a mid-stage trial in 114 patients recovering from bowel surgery; ipamorelin did not significantly improve the time to tolerating a meal or any other measure, and the company then stopped developing it. A much larger trial of the same kind, in 320 patients at 45 sites, finished in 2014 and its results were never published. No human trial has tested ipamorelin for muscle growth, fat loss, sleep, anti-ageing, injury recovery or growth hormone deficiency, and the FDA confirmed in 2024 that it could find no human data for any of these, nor any human data at all on the injection-under-the-skin route that products are sold for.

Key studies

FDA status
Not approved. Not on the pharmacy compounding list. FDA flags it as a significant safety risk.
In sport
Prohibited at all times; named in S2.2.4 as a growth hormone secretagogue.

All 14 studies on the Ipamorelin page

Tesamorelin

Approved medicine

Tesamorelin is a man-made version of the body's growth hormone-releasing hormone; it is an FDA-approved prescription medicine for one narrow use (excess belly fat in adults with HIV and lipodystrophy), backed by two phase 3 trials, and the evidence outside that use is small and mixed.

In adults with HIV and excess abdominal fat, two randomized, placebo-controlled phase 3 trials of about 400 people each showed that tesamorelin reduced deep belly fat by roughly 14% to 18% over 26 weeks, without changing body weight. The fat returned within 26 weeks in people switched to placebo. Smaller trials found less liver fat in people with HIV, and one-year effects on belly fat in obese adults without HIV, but those are not approved uses. No trial has shown fewer heart attacks, strokes or deaths, the label says long-term cardiovascular safety has not been established, and two small trials on thinking and memory gave conflicting results.

Key studies

FDA status
Approved prescription medicine (Egrifta) for HIV-related belly fat only. Research-use versions sold online are unapproved.
In sport
Prohibited at all times. Named in S2.2.4 of the 2026 and 2027 Lists.

All 14 studies on the Tesamorelin page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.